Bone Microstructure in Response to Vitamin D3 Supplementation: A Randomized Placebo-Controlled Trial
Vitamin D supplementation is often used in the prevention and treatment of osteoporosis, but the role of vitamin D has lately been questioned. We aimed to investigate the effect of 3 months of daily vitamin D3 supplementation (70 µg [2800 IU] vs. placebo) initiated in winter months on bone health. This study is a double-blinded placebo-controlled randomized trial. Bone health was assessed by bone turnover markers, DXA, HRpQCT, and QCT scans. The participants were 81 healthy postmenopausal women with low 25(OH)D (< 50 nmol/l) and high PTH levels (> 6.9 pmol/l) at screening. Vitamin D3 supplementation significantly increased levels of 25(OH)D and 1,25(OH)2D by 59 nmol/l and 19 pmol/l, respectively, whereas PTH was reduced by 0.7 pmol/l (all p < 0.0001). Compared with placebo, vitamin D3 did not affect bone turnover markers, aBMD by DXA or trabecular bone score. Vitamin D3 increased trabecular vBMD (QCT scans) in the trochanter region (0.4 vs. − 0.7 g/cm3) and the femoral neck (2.1 vs. − 1.8 g/cm3) pall < 0.05. HRpQCT scans of the distal tibia showed reduced trabecular number (− 0.03 vs. 0.05 mm−1) and increased trabecular thickness (0.001 vs. − 0.005 mm), as well as an improved estimated bone strength as assessed by failure load (0.1 vs. − 0.1 kN), and stiffness (2.3 vs. − 3.1 kN/mm pall ≤ 0.01). Changes in 25(OH)D correlated significantly with changes in trabecular thickness, stiffness, and failure load. Three months of vitamin D3 supplementation improved bone strength and trabecular thickness in tibia, vBMD in the trochanter and femoral neck, but did not affect aBMD.
KeywordsVitamin D PTH BMD Trabecular bone microarchitecture Estimated bone strength
We acknowledge the funding from Aarhus University, The Augustinus Foundation, Toyota Foundation, A.P. Møller & wife Chastine MC-Kinney Møllers Foundation, and P. A. Messerschmidt & wife foundation. Orkla Health donated vitamin D and vitamin D placebo tablets free of charge, but had no influence on analyses and interpretation of data. Most importantly, we thank all participants for their extraordinary enthusiasm and cooperativeness. We acknowledge the Danish Health Data Authority, Orkla Health A/S, laboratory technicians, the hospital pharmacy and the Department of Radiology, Aarhus University Hospital.
LSB: study design, collection of data; analysis, drafting the manuscript, responsible for data integrity analysis. LLR: data collection, critical revision, and approval of the manuscript. LRo and TS: study design, critical revision, and approval of the manuscript. LRe: study design, analysis, and interpretation of data, as well as critical revision and approval of the manuscript.
Compliance with Ethical Standards
Conflict of interest
Lise Sofie Bislev, Lene Langagergaard Rødbro, Lars Rolighed, Tanja Sikjaer, and Lars Rejnmark declare that they have no conflict of interest and no competing financial interests.
We performed the study in accordance to the Helsinki II declaration considering biomedical research and obtained informed, written consent from all participants.
Human and Animal Rights
The study was approved by the Danish Data Protection Agency (1-16-02-492-14), the Regional Committee on Biomedical Research Ethics (1-10-72-326-14), the Danish Health Authority (2014-003645-10) and Danish Health Data Authority (FSEID-00001274). The local unit for Good Clinical Practice at Aarhus University Hospital monitored the study. Clinicaltrials.gov identifier: #NCT02572960.
All study participants gave their written informed consent.
- 5.Sahota O, Mundey MK, San P et al (2004) The relationship between vitamin D and parathyroid hormone: calcium homeostasis, bone turnover, and bone mineral density in postmenopausal women with established osteoporosis. Bone 35:312–319. https://doi.org/10.1016/j.bone.2004.02.003 CrossRefPubMedGoogle Scholar
- 18.Hermann AP, Thomsen J, Vestergaard P, Mosekilde LCP (1999) Assessment of calcium intake. A quick method comparerd to a 7 days food diary. Calcif Tissue Int 82Google Scholar
- 26.Bislev LS, Langagergaard Rødbro L, Bech JN et al (2018) The effect of vitamin D3 supplementation on markers of cardiovascular health in hyperparathyroid, vitamin D insufficient women: a randomized placebo-controlled trial. Endocrine. https://doi.org/10.1007/s12020-018-1659-4 CrossRefPubMedGoogle Scholar
- 27.Lima GL, Paupitz JA, Aikawa NE et al (2017) A randomized double-blind placebo-controlled trial of vitamin D supplementation in juvenile-onset systemic lupus erythematosus: positive effect on trabecular microarchitecture using HR-pQCT. Osteoporos Int. https://doi.org/10.1007/s00198-017-4316-5 CrossRefPubMedGoogle Scholar
- 29.Cheung TF, Cheuk KY, Yu FWP et al (2016) Prevalence of vitamin D insufficiency among adolescents and its correlation with bone parameters using high-resolution peripheral quantitative computed tomography. Osteoporos Int 27:2477–2488. https://doi.org/10.1007/s00198-016-3552-4 CrossRefPubMedGoogle Scholar
- 31.Touvier M, Deschasaux M, Montourcy M et al (2014) Interpretation of plasma PTH concentrations according to 25OHD status, gender, age, weight status, and calcium intake: importance of the reference values. J Clin Endocrinol Metab 99:1196–1203. https://doi.org/10.1210/jc.2013-3349 CrossRefPubMedGoogle Scholar
- 37.Lai JKC, Lucas RM, Clements MS et al (2010) Hip fracture risk in relation to vitamin D supplementation and serum 25-hydroxyvitamin D levels: a systematic review and meta-analysis of randomised controlled trials and observational studies. BMC Public Health 10:331. https://doi.org/10.1186/1471-2458-10-331 CrossRefPubMedPubMedCentralGoogle Scholar
- 45.Joo NS, Dawson-Hughes B, Kim YS et al (2013) Impact of calcium and vitamin D insufficiencies on serum parathyroid hormone and bone mineral density: analysis of the fourth and fifth Korea National Health and Nutrition Examination Survey (KNHANES IV-3, 2009 and KNHANES V-1, 2010). J Bone Miner Res 28:764–770. https://doi.org/10.1002/jbmr.1790 CrossRefPubMedGoogle Scholar